Norwegian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
immunostimulator/neoplasms
Koblingen er lagret på utklippstavlen
Side 1 fra 101 resultater
Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to the field of immune-based therapeutic agents for cancer.
BACKGROUND
The Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) is a variable RNA binding peptide of 86 to 110 amino acids in length that is encoded on two
Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to the field of immune-based therapeutic agents for cancer.
BACKGROUND
The Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) is a variable RNA binding peptide of 86 to 110 amino acids in length that is encoded on two
Treatment of cancers with immunostimulatory HIV Tat derivative polypeptides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to the field of immune-based therapeutic agents for cancer.
BACKGROUND
Immune checkpoints represent inhibitory molecules that result in the inhibition of an effective immune response towards cancer which can result in tumor evasion. Immune
Treatment of cancers with immunostimulatory HIV tat derivative polypeptides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates to the field of immune-based therapeutic agents for cancer.
BACKGROUND
Immune checkpoints represent inhibitory molecules that result in the inhibition of an effective immune response towards cancer which can result in tumor evasion. Immune
Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is the U.S. National Stage of International Application No. PCT/JP2005/000238, filed Jan. 12, 2005, which, in turn, claims the benefit of Japanese Patent Application No. 2004-005186, filed Jan. 13, 2004.
TECHNICAL FIELD
The present invention
Immunostimulator for animals and humans, and method of preventing animal and human infectious diseases and cancer
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The invention relates generally to an immunostimulator of all animals and humans, feed, veterinary pharmaceuticals, beverages, food, health food, and pharmaceuticals containing said immunostimulator, infectious diseases that are subject for administration of said
Method of treating cancer using immunostimulatory oligonucleotides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least one unmethylated CpG dinucleotide which are immunostimulatory.
BACKGROUND OF THE INVENTION
In the 1970s, several investigators
Methods of treating cancer using immunostimulatory oligonucleotides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates generally to oligonucleotides and more specifically to oligonucleotides which have a sequence including at least one unmethylated CpG dinucleotide which are immunostimulatory.
BACKGROUND OF THE INVENTION
In the 1970s, several investigators
Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC)
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Apr. 1, 2013, is named 067802.sub.13CU14.sub.13 US2_Sequence_isting.txt and is 77,865 bytes in size.
The
Self antigen vaccines for treating B cell lymphomas and other cancers
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
This invention, in the field of molecular biology, immunology and medicine, relates to a polypeptide vaccine, produced in plants, for inducing an immune response to a self-antigen (which is normally clonally expressed) on the surface of certain tumor cells. In a preferred
C-class oligonucleotide analogs with enhanced immunostimulatory potency
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids.
BACKGROUND OF THE INVENTION
Bacterial DNA has immune stimulatory effects to activate B cells and natural killer cells, but
Immunostimulatory oligoribonucleotides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The invention relates generally to the field of immunology, and more particularly to immunostimulatory molecules. More specifically the invention relates to ribonucleic acid (RNA) molecules, including oligoribonucleotides, with immunostimulatory activity.
BACKGROUND OF THE
Immunostimulatory oligoribonucleotides
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
FIELD OF THE INVENTION
The invention relates generally to the field of immunology, and more particularly to immunostimulatory molecules. More specifically the invention relates to ribonucleic acid (RNA) molecules, including oligoribonucleotides, with immunostimulatory activity.
BACKGROUND OF THE
Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The content of the electronically submitted substitute sequence listing, file name: 1700.sub.--0220004SEQ IDListing.ascii.txt; Size: 151,531 bytes; and Date of Creation: Jun. 22, 2012, filed herewith, is incorporated herein by reference in its
Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY
The content of the electronically submitted sequence listing Name: 1700_0220004_RevisedListing_ascii.txt; Size 152,065 bytes; and Date of Creation: Aug. 10, 2012) filed herewith, is incorporated herein by reference in its entirety.
BACKGROUND OF
Den mest komplette databasen med medisinske urter støttet av vitenskap
- Fungerer på 55 språk
- Urtekurer støttet av vitenskap
- Urtegjenkjenning etter bilde
- Interaktivt GPS-kart - merk urter på stedet (kommer snart)
- Les vitenskapelige publikasjoner relatert til søket ditt
- Søk medisinske urter etter deres effekter
- Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter
Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning
